Fresenius Medical Care Cliffview is a medicare approved dialysis facility center in El Paso, Texas and it has 21 dialysis stations. It is located in El Paso county at 1225 E Cliff Drive, El Paso, TX, 79902. You can reach out to the office of Fresenius Medical Care Cliffview at (915) 532-6411. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Fresenius Medical Care Cliffview has the following ownership type - Profit. It was first certified by medicare in August, 1994. The medicare id for this facility is 452674 and it accepts patients under medicare ESRD program.
| Name | Fresenius Medical Care Cliffview |
|---|---|
| Location | 1225 E Cliff Drive, El Paso, Texas |
| No. of Dialysis Stations | 21 |
| Medicare ID | 452674 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 1225 E Cliff Drive, El Paso, Texas, 79902 | |
| (915) 532-6411 | |
News Archive
Almost 8% of women have extremely high breast density, which can make it harder for health professionals to detect breast cancer on a screening mammogram. These women are also more likely to develop breast cancer in the future.
Today Biogen Idec and Elan Corporation, plc announced that they have submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) requesting updates to the TYSABRI (natalizumab) labels.
Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody produced at St. Jude Children's Research Hospital.
Research funded in part by the Canadian Cancer Society may lead to a genetic screening test that could help families who are at high risk for cancer.
› Verified 2 days ago
| NPI Number | 1356453245 |
| Organization Name | Bma Cliffview |
| Doing Business As | Bio-medical Applications Of Texas, Inc. |
| Address | 1225 E Cliff Dr El Paso, Texas, 79902 |
| Phone Number | (915) 532-6411 |
News Archive
Almost 8% of women have extremely high breast density, which can make it harder for health professionals to detect breast cancer on a screening mammogram. These women are also more likely to develop breast cancer in the future.
Today Biogen Idec and Elan Corporation, plc announced that they have submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) requesting updates to the TYSABRI (natalizumab) labels.
Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody produced at St. Jude Children's Research Hospital.
Research funded in part by the Canadian Cancer Society may lead to a genetic screening test that could help families who are at high risk for cancer.
› Verified 2 days ago
| Dialysis patients with Hemoglobin data | 21 |
News Archive
Almost 8% of women have extremely high breast density, which can make it harder for health professionals to detect breast cancer on a screening mammogram. These women are also more likely to develop breast cancer in the future.
Today Biogen Idec and Elan Corporation, plc announced that they have submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) requesting updates to the TYSABRI (natalizumab) labels.
Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody produced at St. Jude Children's Research Hospital.
Research funded in part by the Canadian Cancer Society may lead to a genetic screening test that could help families who are at high risk for cancer.
› Verified 2 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 68 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 533 |
| Percentage of adult patients getting regular hemodialysis at the center | 97 |
| Pediatic patients getting regular hemodialysis at the center | 1 |
| Pediatric patient months included in in Kt/V greater than or eqaul to 1.2 | 10 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Almost 8% of women have extremely high breast density, which can make it harder for health professionals to detect breast cancer on a screening mammogram. These women are also more likely to develop breast cancer in the future.
Today Biogen Idec and Elan Corporation, plc announced that they have submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) requesting updates to the TYSABRI (natalizumab) labels.
Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody produced at St. Jude Children's Research Hospital.
Research funded in part by the Canadian Cancer Society may lead to a genetic screening test that could help families who are at high risk for cancer.
› Verified 2 days ago
| Adult patients getting regular peritoneal dialysis at the center | 17 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 108 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 94 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
Almost 8% of women have extremely high breast density, which can make it harder for health professionals to detect breast cancer on a screening mammogram. These women are also more likely to develop breast cancer in the future.
Today Biogen Idec and Elan Corporation, plc announced that they have submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) requesting updates to the TYSABRI (natalizumab) labels.
Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody produced at St. Jude Children's Research Hospital.
Research funded in part by the Canadian Cancer Society may lead to a genetic screening test that could help families who are at high risk for cancer.
› Verified 2 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Fresenius Medical Care Cliffview with elevated calcium levels.
| Patients with hypercalcemia | 81 |
| Hypercalcemia patient months | 649 |
| Patients with Serumphosphor | 89 |
| Patients with Serumphosphor less than 3.5 mg/dL | 11 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 26 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 26 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 22 |
| Patients with Serumphosphor greater than 7 mg/dL | 14 |
News Archive
Almost 8% of women have extremely high breast density, which can make it harder for health professionals to detect breast cancer on a screening mammogram. These women are also more likely to develop breast cancer in the future.
Today Biogen Idec and Elan Corporation, plc announced that they have submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) requesting updates to the TYSABRI (natalizumab) labels.
Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody produced at St. Jude Children's Research Hospital.
Research funded in part by the Canadian Cancer Society may lead to a genetic screening test that could help families who are at high risk for cancer.
› Verified 2 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 68 |
| Patient months included in arterial venous fistula and catheter summaries | 296 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 74 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 8 |
News Archive
Almost 8% of women have extremely high breast density, which can make it harder for health professionals to detect breast cancer on a screening mammogram. These women are also more likely to develop breast cancer in the future.
Today Biogen Idec and Elan Corporation, plc announced that they have submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) requesting updates to the TYSABRI (natalizumab) labels.
Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody produced at St. Jude Children's Research Hospital.
Research funded in part by the Canadian Cancer Society may lead to a genetic screening test that could help families who are at high risk for cancer.
› Verified 2 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 52 |
| Hospitalization Rate in facility | 205.6 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 369.6 |
| Hospitalization Rate: Lower Confidence Limit | 119.2 |
News Archive
Almost 8% of women have extremely high breast density, which can make it harder for health professionals to detect breast cancer on a screening mammogram. These women are also more likely to develop breast cancer in the future.
Today Biogen Idec and Elan Corporation, plc announced that they have submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) requesting updates to the TYSABRI (natalizumab) labels.
Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody produced at St. Jude Children's Research Hospital.
Research funded in part by the Canadian Cancer Society may lead to a genetic screening test that could help families who are at high risk for cancer.
› Verified 2 days ago
The rate of readmission show you whether patients who were being treated regularly at Fresenius Medical Care Cliffview were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 32.5 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 45.1 |
| Readmission Rate: Lower Confidence Limit | 21.4 |
News Archive
Almost 8% of women have extremely high breast density, which can make it harder for health professionals to detect breast cancer on a screening mammogram. These women are also more likely to develop breast cancer in the future.
Today Biogen Idec and Elan Corporation, plc announced that they have submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) requesting updates to the TYSABRI (natalizumab) labels.
Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody produced at St. Jude Children's Research Hospital.
Research funded in part by the Canadian Cancer Society may lead to a genetic screening test that could help families who are at high risk for cancer.
› Verified 2 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Fresenius Medical Care Cliffview get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 1.03 (As Expected) |
| SIR: Upper Confidence Limit | 2.49 |
| SIR: Lower Confidence Limit | .33 |
News Archive
Almost 8% of women have extremely high breast density, which can make it harder for health professionals to detect breast cancer on a screening mammogram. These women are also more likely to develop breast cancer in the future.
Today Biogen Idec and Elan Corporation, plc announced that they have submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) requesting updates to the TYSABRI (natalizumab) labels.
Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody produced at St. Jude Children's Research Hospital.
Research funded in part by the Canadian Cancer Society may lead to a genetic screening test that could help families who are at high risk for cancer.
› Verified 2 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Fresenius Medical Care Cliffview's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 44 |
| Transfusion Rate in facility | 34.7 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 121.1 |
| Transfusion Rate: Lower Confidence Limit | 11.6 |
News Archive
Almost 8% of women have extremely high breast density, which can make it harder for health professionals to detect breast cancer on a screening mammogram. These women are also more likely to develop breast cancer in the future.
Today Biogen Idec and Elan Corporation, plc announced that they have submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) requesting updates to the TYSABRI (natalizumab) labels.
Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody produced at St. Jude Children's Research Hospital.
Research funded in part by the Canadian Cancer Society may lead to a genetic screening test that could help families who are at high risk for cancer.
› Verified 2 days ago
The rate of mortality show you whether patients who were being treated regularly at Fresenius Medical Care Cliffview lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 355 |
| Mortality Rate in facility | 18.7 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 25.6 |
| Mortality Rate: Lower Confidence Limit | 13.2 |
News Archive
Almost 8% of women have extremely high breast density, which can make it harder for health professionals to detect breast cancer on a screening mammogram. These women are also more likely to develop breast cancer in the future.
Today Biogen Idec and Elan Corporation, plc announced that they have submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) requesting updates to the TYSABRI (natalizumab) labels.
Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody produced at St. Jude Children's Research Hospital.
Research funded in part by the Canadian Cancer Society may lead to a genetic screening test that could help families who are at high risk for cancer.
› Verified 2 days ago
Fresenius Medical Care El Paso Gateway Location: 10767 Gateway West, El Paso, Texas, 79935 Phone: (915) 599-2891 |
Fresenius Medical Care Cliffview Location: 1225 E Cliff Drive, El Paso, Texas, 79902 Phone: (915) 532-6411 |
News Archive
Almost 8% of women have extremely high breast density, which can make it harder for health professionals to detect breast cancer on a screening mammogram. These women are also more likely to develop breast cancer in the future.
Today Biogen Idec and Elan Corporation, plc announced that they have submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) requesting updates to the TYSABRI (natalizumab) labels.
Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody produced at St. Jude Children's Research Hospital.
Research funded in part by the Canadian Cancer Society may lead to a genetic screening test that could help families who are at high risk for cancer.
› Verified 2 days ago